TABLE 1.
Cancer types | Sponsor/Company | Target | References |
---|---|---|---|
Melanoma | BMS | PD-1 | 38, 40, 42, 43, 44, 49, 51, 60 |
PD-L1 | 39 | ||
Merck | PD-1 | 41, 48 | |
Roche/Genentech | PD-L1 | 45, 61 | |
Non small-cell lung
cancer (NSCLC) |
BMS | PD-1 | 40 49 |
PD-L1 | 39 | ||
Merck | PD-1 | 58, 59 | |
Roche/Genentech | PD-L1 | 45 | |
AstraZeneca/MedImmune | PD-L1 | 54, 57 | |
Renal cell cancer (RCC) | BMS | PD-1 | 38, 40, 42, 46, 49 |
PD-L1 | 39 | ||
Roche/Genentech | PD-L1 | 45 | |
Urothelial bladder
cancer (UBC) |
Merck | PD-1 | 56 |
Roche/Genentech | PD-L1 | 47 | |
Hodgkin’s lymphoma | BMS | PD-1 | 50 |
Head and neck cancer | Merck | PD-1 | 55 |
Roche/Genentech | PD-L1 | 45, 53 | |
AstraZeneca/MedImmune | PD-L1 | 54 | |
Triple negative breast cancer | Merck | PD-1 | 52 |
Roche/Genentech | PD-L1 | 62 |
BMS, Bristol-Myers Squibb